| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| Product Name: | BPIQ-I | | Synonyms: | 8-[(3-BROMOPHENYL)AMINO]-3-METHYL-3H-IMIDAZO[4,5-GAMMA]-QUINAZOLINE;8-[(3-BROMOPHENYL)AMINO]-3-METHYL-3H-IMIDAZO[4,5-G]-QUINAZOLINE;BPIQ-I;N-(3-bromophenyl)-3-methylimidazo[4,5-g]quinazolin-8-amine;3H-Imidazo[4,5-g]quinazolin-8-amine, N-(3-bromophenyl)-3-methyl- | | CAS: | 174709-30-9 | | MF: | C16H12BrN5 | | MW: | 354.2 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | BPIQ-I Chemical Properties |
| Boiling point | 535.5±60.0 °C(Predicted) | | density | 1.62±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | | form | A crystalline solid | | pka | 5.12±0.50(Predicted) |
| | BPIQ-I Usage And Synthesis |
| Description | BPIQ-I is a quinazoline that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (IC50 = 0.025 nM). It can inhibit the growth of SKOV3 and MDA-468 tumor cell lines with EC50 values of 6.5 and 30 μM, respectively. | | Uses | BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. BPIQ-I shows anti-proliferative actively[1][2]. | | References | [1] Rae JM, et al. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat. 2004 Jan;83(2):99-107. DOI:10.1023/B:BREA.0000010702.10130.29
[2] Zhou Y, et al. Role of a tyrosine kinase in the CO2-induced stimulation of HCO3- reabsorption by rabbit S2 proximal tubules. Am J Physiol Renal Physiol. 2006 Aug;291(2):F358-67. DOI:10.1152/ajprenal.00520.2005 |
| | BPIQ-I Preparation Products And Raw materials |
|